Cyclazodone

# Research Output: Cyclazodone

## Chemical Identity

**Confirmed via PubChem (CID 135438121) and Chemsrc (CAS 14461-91-7):**

| Property | Value | Source |
|---|---|---|
| IUPAC Name | 2-cyclopropylimino-5-phenyl-1,3-oxazolidin-4-one | PubChem [Ref 26] |
| Systematic name | 2-(Cyclopropylamino)-5-phenyl-2-oxazolin-4-one | NCATS [Ref 26] |
| CAS Number | 14461-91-7 | Chemsrc [Ref 17] |
| PubChem CID | 135438121 | PubChem |
| Molecular Formula | C₁₂H₁₂N₂O₂ | PubChem / Chemsrc [Ref 17] |
| Molecular Weight | 216.24 g/mol | PubChem / Chemsrc [Ref 17] |
| SMILES | O=C1NC(=NC2CC2)OC1c1ccccc1 | Chemsrc [Ref 17] |
| InChIKey | DNRKTAYPGADPGW-UHFFFAOYSA-N | PubChem [Ref 17] |
| UNII (FDA) | O8U55ZRL9K | NCATS Inxight [Ref 26] |
| INN Registry | 2173 | NCATS Inxight [Ref 26] |
| Density | 1.4 g/cm³ | Chemsrc [Ref 17] |
| Boiling Point | 334.8 °C at 760 mmHg | Chemsrc [Ref 17] |
| Flash Point | 156.3 °C | Chemsrc [Ref 17] |
| LogP | 1.219 | Chemsrc [Ref 17] |

**Stereochemistry:** Racemic mixture with one undefined stereocenter (NCATS Inxight [Ref 26]). No published data on enantiomer-specific activity.

**Synonyms confirmed:** Cyclazodone (INN), N-cyclopropylpemoline, cyclopropyl pemoline, 5-phenyl-2-cyclopropylamino-4-oxazolinone.

**Discrepancies with brief seed data:**
- Brief lists no SMILES; confirmed SMILES: `O=C1NC(=NC2CC2)OC1c1ccccc1`
- Brief lists no CAS, PubChem CID, InChIKey; all confirmed above
- Chemical class in brief: "Substituted aminorexe" — confirmed; cyclazodone belongs to the 4-oxazolidinone class and is structurally related to aminorex (2-amino-5-phenyl-2-oxazoline), pemoline, fenozolone, and thozalinone. The "substituted aminorex" designation is acceptable though the oxazolidinone (4-oxooxazolidine) ring distinguishes it from strict aminorex (2-amino-2-oxazoline) derivatives.

---

## Pharmacology

### Mechanism of Action

Cyclazodone is classified as a norepinephrine-dopamine reuptake inhibitor (NDRI) with stimulant actions similar to those of dexamphetamine (Docherty 2008 [Ref 19]; Luethi & Liechti 2020 [Ref 7]). These classifications derive from the pharmacology of its parent compound pemoline and the broader aminorex/oxazolidinone class.

**Pemoline's established mechanism** (the closest structurally published comparator): pemoline is classified as a predominantly dopaminergic monoaminomimetic (Docherty 2008 [Ref 19]). It functions primarily as a dopamine reuptake inhibitor with weak dopamine-releasing properties. Pemoline demonstrates minimal activity at norepinephrine pathways compared to amphetamine or methylphenidate (Stevenson & Wolraich 1989 [Ref — community ADHD review context]; Mignot et al. 1993 [Ref — canine narcolepsy study]).

**Aminorex class comparators:** Aminorex analogs act primarily via monoamine transporter inhibition or release. Among characterized aminorex derivatives:
- 4-MAR (4-methylaminorex): Preferential NET and DAT inhibition, amphetamine-like profile (Rickli et al. 2019 [Ref 2])
- 4,4'-DMAR: Potent inhibition of all three transporters (DAT, NET, SERT), MDMA-like serotonergic profile (Rickli et al. 2019 [Ref 2]; Brandt et al. 2014 [Ref 4])
- Cyclazodone's specific Ki/EC50 values at DAT, NET, or SERT have **not been published** in peer-reviewed literature.

**TAAR1 speculation:** Some community and nootropic sources claim cyclazodone activates TAAR1 (Trace Amine-Associated Receptor 1). This is speculative extrapolation from structural class similarities to amphetamine-like TAAR1 agonists. **No published research has characterized cyclazodone as a TAAR1 ligand.** This should not be presented as established pharmacology.

**⚠️ FLAG:** No published binding affinity (Ki or EC50) data for cyclazodone at any molecular target. All mechanistic claims derive from structural analog inference (pemoline pharmacology, aminorex class data).

### Pharmacokinetics

**No published human or animal pharmacokinetic studies exist for cyclazodone itself.**

Relevant inference from analog data:
- **Pemoline (structural comparator):** Oral absorption rapid; peak serum levels 2–4 hours post-dose; elimination half-life 7–12 hours (longer with age); ~50% plasma protein binding; hepatic metabolism; ~50% excreted unchanged in urine (Pemoline pharmacokinetics, Clinical Pharmacokinetics 1985 [Ref 27])
- **N-methyl-cyclazodone toxicokinetics:** CYP2A6-mediated N-demethylation produces cyclazodone as the primary phase I metabolite; low-to-moderate plasma protein binding for both N-methyl-cyclazodone and cyclazodone (Gampfer et al. 2026 [Ref 18])

**⚠️ FLAG — CRITICAL SEED DATA ERROR:** The brief's tolerance data lists a **half-life of "5 days"** for cyclazodone. This is not supported by any published source. Community reports describe effects lasting 4–7 hours (consistent with a drug half-life in the hour range, not days). Pemoline's half-life is 7–12 hours. The "5 days" figure in the tolerance table almost certainly refers to the tolerance half-life (time for tolerance to decay by 50%), not the elimination half-life of the drug itself — but even this value is unverified. The generation agent should not present "5-day half-life" as an elimination half-life. The tolerance buildup/reset data (half-life: 5 days; full reset: 1.5 weeks) may be community consensus estimates for tolerance decay kinetics, not pharmacokinetic half-life, but this is not confirmed.

**Oral bioavailability** and Tmax are not published for cyclazodone. Based on community reports of 20–45 minute onset, oral absorption appears reasonably rapid.

**CYP enzymes:** CYP2A6 confirmed for N-methyl-cyclazodone metabolism to cyclazodone (Gampfer et al. 2026 [Ref 18]). CYP enzymes responsible for cyclazodone's own downstream metabolism are not published.

### Duration of Effects

Community consensus (PsychonautWiki [Ref 14]; Bluelight megathread [Ref 16]): Onset 20–45 minutes; total duration 5–7 hours, oral. This is consistent with seed data and with the pharmacological profile of stimulants with similar structures.

---

## History

### Discovery and Synthesis

Cyclazodone was synthesized in the early 1960s by researchers at **Les Laboratoires Dausse** (Paris, France). The compound was described in **British patent GB 1,005,738** (issued 1965), with inventors listed as De Marne V, Pierre D, Guidicelli RL, and Najer H. The patent described 5-phenyl-2-cyclopropylamino-4-oxazolinone and its non-toxic acid addition salts as a central nervous system stimulant and anorexic agent suitable for oral administration.

Some sources attribute development to **American Cyanamid Company** (NCATS Inxight [Ref 26]; Graves 2023 [Ref 15]). This may reflect patent licensing or parallel development; the precise institutional history requires further archival verification. The British patent assignee is Les Laboratoires Dausse; American Cyanamid involvement is reported but not confirmed from patent records accessed in this research.

The rationale for development was to produce a safer CNS stimulant than pemoline and other N-alkyl-substituted pemoline derivatives, with more favorable therapeutic index. Animal studies reportedly showed that cyclazodone produced stimulatory effects including enhanced performance in continuous avoidance tasks in rats, with actions comparable to d-amphetamine and pemoline. Cardiotoxicity in mice was reportedly less than dexamphetamine.

Cyclazodone was patented but **never entered clinical development** and was never approved by any regulatory agency for human use (NCATS Inxight: status "Investigational" [Ref 26]). No human clinical trials were registered or completed.

### Market Appearance as Research Chemical

Cyclazodone had no documented history of recreational human use prior to approximately **2017**, when it appeared on online research chemical markets, primarily marketed as a nootropic powder (PsychonautWiki [Ref 14]; Graves 2023 [Ref 15]). The compound attracted attention from the psychonaut and nootropic communities as a cognitive enhancer and stimulant alternative to pharmaceutical ADHD medications.

N-methyl-cyclazodone (CAS 14461-92-8) emerged on the RC market as a related and reportedly more potent compound. Metabolically, N-methyl-cyclazodone is N-demethylated by CYP2A6 to produce cyclazodone as its primary active phase I metabolite (Gampfer et al. 2026 [Ref 18]).

### Regulatory Context of Parent Class

**Aminorex** (2-amino-5-phenyl-2-oxazoline), the structural parent of this compound class, was marketed as an anorectic in Switzerland, Austria, and Germany from 1965 to 1968. Its withdrawal followed a 20-fold increase in primary pulmonary hypertension incidence in Switzerland (Kay et al. 1971 [Ref 5]; Frank et al. 1997 [Ref 6]).

**Pemoline**, the closest structural analog of cyclazodone, was approved for ADHD treatment in the US (1975) but was withdrawn from most markets by the mid-2000s due to fatal idiosyncratic hepatotoxicity (Etwel et al. 2008 [Ref 12]; Marotta & Roberts 1998 [Ref 9]). This regulatory history is directly relevant to cyclazodone's risk profile.

**4,4'-DMAR** (a ring-substituted methylaminorex) was associated with at least 26 deaths in Europe in 2013 (Brandt et al. 2014 [Ref 4]), demonstrating the serious fatality potential of aminorex-class analogs.

---

## Subjective Effects

No controlled human studies of cyclazodone's subjective effects exist. All data derives from user reports.

**Reported effects from community sources (Bluelight megathread [Ref 16]; PsychonautWiki [Ref 14]; Nootropics Junkie [Ref 22]):**

**Cognitive/nootropic effects:**
- Enhanced focus and concentration (described as comparable to amphetamine by some users)
- Improved verbal fluency and information retention
- Mild mood elevation; antidepressant-like quality reported at medium doses
- Motivation enhancement; wakefulness
- Low euphoric potential compared to amphetamine — described as "clean" stimulation
- Comparison to modafinil in terms of subtle effect profile

**Stimulant/physical effects:**
- Physical stimulation and energy without pronounced jitteriness at low-to-moderate doses
- Increased heart rate (tachycardia); one user report of HR up to 200 BPM at high doses
- Elevated blood pressure
- Appetite suppression
- Dry mouth, dehydration

**Adverse effects reported:**
- Physical anxiety at higher doses (users report this fades with continued use)
- Fatigue and malaise upon discontinuation following daily use
- Headaches (some cases requiring benzodiazepine intervention per user reports)
- Compulsive redosing urge reported at higher doses

**Dose ranges from community consensus (PsychonautWiki [Ref 14]):**
- Threshold: 5 mg oral
- Light: 5–15 mg oral
- Common: 15–25 mg oral
- Strong: 25–60 mg oral
- Heavy: 60+ mg oral (hepatotoxicity warning noted at heavy doses)
- Most users report effects at 10–25 mg; ceiling effects reported at ~50 mg

**Duration (community consensus [Ref 14, 16]):**
- Onset: 20–45 minutes oral
- Total duration: 5–7 hours oral
- No significant advantage observed with intranasal administration per user reports

**Seed data doses and durations confirmed by community consensus; no published controlled study data available.**

---

## Safety & Toxicity

### Published Case Data

**N-Methyl-cyclazodone toxicity case** (CFSRE 2022 [Ref 13]; Basile et al., NACCT 2022 abstract): A 38-year-old male self-administered approximately 5 grams of N-methyl-cyclazodone dissolved in water over 5 days to self-treat attention deficit disorder. He was concurrently taking prescribed fluoxetine and aripiprazole for bipolar disorder. He presented with:
- Uncontrollable choreiform (dance-like) body movements affecting the entire body
- Inattention, restlessness, tremor
- Tachycardia: HR 110/min
- Hypertension: 150/90 mmHg
- Tachypnea: RR 24/min
- Dilated, reactive pupils
- ECG: Sinus tachycardia, **QRS 140 ms, QTc 526 ms** (critically prolonged)
- Creatine kinase elevated: **2954 U/L** (rhabdomyolysis marker)
- Alanine aminotransferase elevated: **104 U/L** (hepatic injury marker)
- Standard urine immunoassay: NEGATIVE (highlighting detection challenge)
- LC-HRMS urinary confirmation: cyclazodone confirmed as metabolite of N-methyl-cyclazodone; pemoline and 4-methylaminorex ruled out

Treatment: IV crystalloid fluids, lorazepam (movement disorder, autonomic hyperactivity), sodium bicarbonate (shortened widened QRS), magnesium supplementation. Symptoms resolved by hospital day 3 with normalizing enzyme levels.

**Clinical significance:** This case demonstrates (1) that cyclazodone is an active phase I metabolite of N-methyl-cyclazodone; (2) QTc prolongation as a serious cardiac risk; (3) rhabdomyolysis potential; (4) hepatotoxic signal (elevated ALT); (5) chorea/movement disorder risk; (6) detection failure on standard immunoassay requiring HRMS confirmation.

**Note:** The case involved N-methyl-cyclazodone at a very high cumulative dose (5g over 5 days) and concurrent SSRI (fluoxetine), complicating attribution of individual effects.

### Hepatotoxicity Concern (Class-Based)

No direct human hepatotoxicity cases from cyclazodone use have been identified in published literature. However, significant concern arises from pemoline's (structural analog) well-documented hepatotoxicity record:

- At least 21 cases of pemoline-related liver failure documented; 13 required liver transplantation or resulted in death (Marotta & Roberts 1998 [Ref 9])
- Approximately 1–2% of pemoline patients developed elevated serum aminotransferases
- Reactions were idiosyncratic and unpredictable — sometimes occurring after years of uneventful use (Berkovitch et al. 1995 [Ref 11]; Pratt & Dubois 1990 [Ref 24])
- Possible autoimmune mechanism proposed (Rosh et al. 1998 [Ref 23])
- Pemoline was withdrawn from US market due to fatal hepatotoxicity (Etwel et al. 2008 [Ref 12])
- Liver transplantation cases documented (Adcock et al. 1998 [Ref 10])
- PsychonautWiki warns of hepatic damage with heavy or sustained cyclazodone use [Ref 14]
- The CFSRE case showed ALT elevation with N-methyl-cyclazodone at high doses [Ref 13]

**⚠️ FLAG:** Hepatotoxicity risk for cyclazodone is class-inferred from pemoline data. Whether cyclazodone causes idiosyncratic hepatotoxicity at therapeutic/recreational doses is **unknown**. This is a major safety gap.

### Cardiovascular Risks (Class-Based)

- Aminorex caused pulmonary arterial hypertension in human users (Kay et al. 1971 [Ref 5]; Frank et al. 1997 [Ref 6]); this class-specific risk has not been evaluated for cyclazodone
- QTc prolongation observed in the N-methyl-cyclazodone toxicity case (QTc 526 ms) [Ref 13]
- Tachycardia and hypertension are consistent effects of monoamine stimulants
- User reports of HR up to 200 BPM at high doses [Ref 22]

### Exact Toxic Dosage

Unknown. No LD50 data published for cyclazodone in any species. Seed data note ("exact toxic dosage is unknown") confirmed as accurate.

### Exact Therapeutic Index

Not established. No clinical development data available.

### Detection

Standard urine immunoassay will not detect cyclazodone (confirmed in CFSRE case [Ref 13]). LC-HRMS required for confirmation.

---

## Harm Reduction

### Contraindications (Class-Based, No Cyclazodone-Specific Data)
- Hepatic impairment or liver disease (structural analog hepatotoxicity; see Safety section)
- Concurrent MAO inhibitors (risk of hypertensive crisis and serotonin syndrome)
- Concurrent tramadol (see Interactions — designated as lethal in database)
- Concurrent MDMA or other serotonergic agents (see Interactions — dangerous)
- Cardiac arrhythmia or prolonged QTc at baseline (QTc prolongation documented in N-methyl-cyclazodone case [Ref 13])
- Pre-existing psychiatric conditions predisposing to stimulant-induced psychosis
- Concurrent SSRI use: the CFSRE case involved fluoxetine co-administration; the interaction profile is unknown but potentially serious [Ref 13]

### Liver Monitoring
Given the structural similarity to pemoline and the ALT elevation observed in the N-methyl-cyclazodone case, liver function monitoring (ALT, AST) would be prudent for any use, especially prolonged or high-dose use. Pemoline-associated hepatotoxicity was sometimes delayed by months to years [Ref 11].

### Testing
Cyclazodone will return a negative result on standard urine immunoassay. Fentanyl test strips and other common reagent tests have not been validated for cyclazodone. HRMS-based laboratory testing is required for definitive identification.

### Dosing Caution
The 60+ mg "heavy" dose threshold carries explicit hepatotoxicity warnings in community sources [Ref 14]. Given complete absence of safety data, doses exceeding the common range (15–25 mg) should be considered high-risk.

---

## Tolerance & Dependence

### Published Data
No published controlled studies on cyclazodone tolerance or dependence exist.

### Seed Data
- Buildup: "develops with prolonged and repeated use" — consistent with class (monoamine stimulants)
- Tolerance half-life listed as "5 days" — **this value is unverified and should be flagged**
- Full tolerance reset listed as "1.5 weeks" — unverified, community-inferred
- Cross-tolerances: dopamine, stimulant — consistent with class

### Community Reports (Bluelight [Ref 16])
Users report fatigue and malaise upon discontinuation following daily use, consistent with dopaminergic hypoactivity after stimulant use. No formal withdrawal syndrome characterized.

### Class-Based Inference
Monoamine reuptake inhibitors typically produce tolerance through receptor downregulation and compensatory adaptive mechanisms. Dependence liability has not been formally assessed for cyclazodone. Pemoline was not classified as a controlled substance (Schedule IV) primarily for abuse potential; however, monoaminomimetic stimulants as a class carry dependence risk proportional to their dopaminergic efficacy.

**⚠️ FLAG:** The tolerance half-life of "5 days" in the seed data does not correspond to any published pharmacokinetic measurement. If this represents the time for 50% tolerance decay after cessation, it may be a community estimate extrapolated from class data, but it is unverified and should not be presented as published pharmacokinetic data.

---

## Interactions

### Tramadol (Designated: Lethal in database)

**Mechanism basis:** Tramadol is both a weak opioid agonist and an SNRI (serotonin/norepinephrine reuptake inhibitor). Tramadol significantly lowers seizure threshold. The first reported death from tramadol involved a combination with multiple serotonergic/noradrenergic drugs (tramadol + venlafaxine + trazodone), producing fatal seizure activity (Ripple et al. 2000 [Ref 20]). Tramadol-induced neurotoxicity in rats involves early elevation of brain serotonin and norepinephrine concentrations (Lagard et al. 2016 [Ref 21]).

**Cyclazodone + tramadol risk:** Cyclazodone's noradrenergic reuptake inhibition would additively increase norepinephrine activity on top of tramadol's own SNRI effect. This combination substantially elevates risk of seizures, serotonin syndrome features, and cardiac arrhythmia. The "lethal" designation in the database is consistent with published tramadol interaction toxicology for noradrenergic/serotonergic combinations.

**⚠️ FLAG:** The lethal classification is class-inferred; no published case reports specifically documenting cyclazodone + tramadol fatality were found.

### MDMA (Designated: Dangerous in database)

**Mechanism basis:** MDMA is a non-selective monoamine releaser with potent serotonergic activity. Combining a dopaminergic/noradrenergic stimulant with MDMA substantially increases monoamine burden, risks hyperthermia, cardiovascular overstimulation, and serotonin toxicity. Aminorex analogs with high serotonergic activity (e.g., 4,4'-DMAR) have been associated with fatalities (Brandt et al. 2014 [Ref 4]).

**⚠️ FLAG:** "Dangerous" classification is class-based. No cyclazodone-specific MDMA interaction data found.

### Alcohol (Designated: Unknown in database)

No published data on cyclazodone + alcohol interaction found. The "unknown" designation in the database is appropriate. Class-based: stimulants generally mask CNS depressant effects of alcohol, increasing risk of dangerous alcohol intake levels and cardiovascular strain.

### Potential Interaction: Fluoxetine/SSRIs

In the CFSRE case, the patient was on fluoxetine concurrently with N-methyl-cyclazodone [Ref 13]. Fluoxetine inhibits CYP2D6 and may inhibit CYP2A6, potentially reducing the N-demethylation of N-methyl-cyclazodone to cyclazodone, or alternatively accumulating cyclazodone. The combined serotonin/norepinephrine burden also increases adverse cardiovascular risk. This interaction is uncharacterized and warrants flagging.

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| United States | Gray area / potentially analog | Pemoline (Schedule IV) is the structural analog; Federal Analogue Act (21 U.S.C. § 813) may apply if intended for human consumption |
| United Kingdom | Banned | Covered by Psychoactive Substances Act 2016 [Ref 28] — blanket ban on all psychoactive substances not specifically exempted |
| Germany | Not controlled (legal gray area) | Not scheduled under BtMG (Narcotics Act) or NpSG (NPS Act); may fall under AMG (Medicines Act) if sold for human use |
| Switzerland | Not controlled (legal gray area) | Not listed in controlled schedules A–D |
| Australia | Banned | Blanket psychoactive substance ban |
| New Zealand | Banned | Blanket psychoactive substance ban |
| Canada | Potentially restricted | Analog laws may apply |
| WADA | Prohibited | Listed as prohibited stimulant in competition (Docherty 2008 [Ref 19]) |

**Note:** Aminorex and 4-methylaminorex are UN Convention on Psychotropic Substances (1971) Schedule I controlled substances. Cyclazodone is structurally distinct (oxazolidinone vs. oxazoline ring system) and is not currently subject to international scheduling as of the research date (May 2026).

---

## Clinical Trials

No clinical trials for cyclazodone were found on ClinicalTrials.gov. The compound has investigational status (never completed clinical development). No phase I–IV trials have been registered or published.

---

## Community Feedback Analysis

**No community feedback was submitted in Part A2 of the brief.**

No community feedback items to assess.

---

## Gaps & Flags

### Critical Safety-Critical Values — Not Verified Against Published Sources

1. **⚠️ Tolerance half-life "5 days"**: No published pharmacokinetic data supports a 5-day half-life for cyclazodone. The effects last 5–7 hours (community consensus). Pemoline's half-life is 7–12 hours. The "5-day" figure in the tolerance table almost certainly represents an estimate of tolerance decay kinetics (not drug elimination), but even this is unverified. **The generation agent must not present this as an elimination half-life.** Recommend editorial review.

2. **⚠️ LD50 / Toxic dosage**: Unknown. No published animal or human toxicity threshold data for cyclazodone. Exact toxic dosage genuinely unknown.

3. **⚠️ Tramadol: lethal interaction designation**: Class-inferred; no published case report of cyclazodone-specifically + tramadol fatality. Mechanism rationale is strong (additive noradrenergic + seizure risk), but the "lethal" label is not confirmed by substance-specific evidence.

4. **⚠️ Binding affinity data (Ki/EC50)**: No published receptor binding or transporter affinity data for cyclazodone at DAT, NET, SERT, or any other target. All pharmacological classification is class-inferred.

5. **⚠️ TAAR1 mechanism claim**: No published evidence for TAAR1 involvement. Community-sourced speculation only. Do not present as confirmed.

### Data Gaps — No Published Sources

- No published human pharmacokinetic studies (bioavailability, Tmax, elimination half-life, protein binding, volume of distribution)
- No published human controlled dosing or efficacy studies
- No published animal in vivo studies for cyclazodone specifically (rat avoidance data mentioned in secondary sources but no peer-reviewed original study located)
- No published cyclazodone-specific hepatotoxicity case reports
- No published CYP enzyme mapping for cyclazodone itself (only for N-methyl-cyclazodone → cyclazodone step via CYP2A6)
- No published withdrawal characterization
- No published reproductive or teratogenic toxicology
- No published neurotoxicity studies

### Contradictions Between Seed Data and Published Sources

- **Brief lists "Substituted aminorexe"** as chemical class: technically accurate but note cyclazodone has a 4-oxazolidinone (4-oxo ring) vs. aminorex's 2-amino-2-oxazoline system — both are oxazoline/oxazolidinone ring compounds with a phenyl group, but they are not identical ring systems
- **"5-day tolerance half-life"**: As noted above, this almost certainly does not represent elimination half-life; see flag above

### Areas Relying on Structural Analogy Rather Than Substance-Specific Data

The following content areas in any generated article would rely on **class inference** rather than cyclazodone-specific evidence:
- Mechanism of action (DAT/NET reuptake inhibition: from pemoline/aminorex class)
- Hepatotoxicity risk (from pemoline)
- Pulmonary hypertension class risk (from aminorex — distant structural analog)
- TAAR1 speculation (from amphetamine class; no cyclazodone-specific evidence)
- Tolerance/dependence profile (from monoamine stimulant class)
- MDMA interaction risk (from combined stimulant class data)
- Tramadol interaction mechanism (from tramadol + serotonergic/noradrenergic drug interactions)

### One Published Peer-Reviewed Case Report Involving Cyclazodone (as Metabolite)

The CFSRE 2022 presentation (presented at NACCT 2022) is the only published clinical case involving cyclazodone (confirmed as urinary metabolite of N-methyl-cyclazodone) [Ref 13]. This is a conference presentation/abstract, not a full peer-reviewed journal article. A full manuscript may exist but was not located via PubMed or Crossref searches as of May 2026.

### One Published Toxicokinetic Study

Gampfer et al. 2026 [Ref 18] in *Metabolites* (DOI: 10.3390/metabo16050291) is a peer-reviewed primary study directly characterizing N-methyl-cyclazodone's toxicokinetics, confirming cyclazodone as the CYP2A6 N-demethylation product. This is the highest-quality source directly relevant to cyclazodone's metabolic role.